Related Experiment Video
Updated: Jun 17, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Bullous lesions in Henoch Schönlein Purpura as indication to start systemic prednisone
S L Den Boer1, Sgma Pasmans1, N M Wulffraat1
1Department of Pediatrics, St Antonius Hospital, Nieuwegein, The NetherlandsDepartment of Pediatric Dermatology/Allergology, Wilhelmina's Children Hospital, University Medical Centre Utrecht, Utrecht, The NetherlandsDepartment of Pediatric Rheumatology and Immunology, Wilhelmina's Children Hospital, University Medical Centre Utrecht, Utrecht, The NetherlandsDepartment of Pediatrics, Meander Medical Centre Amersfoort, Amersfoort, The NetherlandsDepartment of Dermatology, Meander Medical Centre Amersfoort, Amersfoort, The Netherlands.
Unlabelled:
Henoch Schönlein Purpura (HSP) is usually mild and self-limiting, but it may be accompanied by severe complications such as bullous lesions. We describe the use of systemic prednisone in two patients with bullous lesions in HSP. The first patient presented with progressive bullous lesions distributed on the limbs that evolved into painful ulcers and necrosis. These were further complicated by a secondary skin infection. He then received 1 mg/kg/day prednisone after 9 days. Patient 2, a 10-year-old boy, presented with HSP and bullous lesions and received intravenous prednisone 1 mg/kg/day within 48 h after appearance of the bullous lesions. He recovered rapidly without any complications.
Conclusion:
To reduce the severity of HSP related bullous lesions and their sequelae, we would propose starting prednisone (1 mg/kg/day) as soon as the bullae appear. In addition to prednisone, analgesics and specialist skin care for bullae should be started.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Peptic Ulcer
Nephrotic Syndrome III : Nursing Management
